These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

966 related items for PubMed ID: 20880037

  • 1. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [Abstract] [Full Text] [Related]

  • 2. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G.
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [Abstract] [Full Text] [Related]

  • 3. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M, Silva M.
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [Abstract] [Full Text] [Related]

  • 4. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen D, Willemsen A, Whitaker N, Chabannon C.
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [Abstract] [Full Text] [Related]

  • 5. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA, Smith C, MacFarland R, Calandra G.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [Abstract] [Full Text] [Related]

  • 7. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
    Ji MM, Shen YG, Gong JC, Tang W, Xu XQ, Zheng Z, Chen SY, He Y, Zheng X, Zhao LD, Zhao WL, Wu W.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb 14; 44(2):112-117. PubMed ID: 36948864
    [Abstract] [Full Text] [Related]

  • 8. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
    DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, 3101 Investigators.
    J Clin Oncol; 2009 Oct 01; 27(28):4767-73. PubMed ID: 19720922
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.
    Transfusion; 2011 Oct 01; 51(10):2175-82. PubMed ID: 21492180
    [Abstract] [Full Text] [Related]

  • 10. Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study.
    Kim JS, Yoon DH, Park S, Yoon SS, Cho SG, Min CK, Lee JJ, Yang DH, Kwak JY, Eom HS, Kim WS, Kim H, Do YR, Moon JH, Lee J, Suh C.
    Ann Hematol; 2016 Mar 01; 95(4):603-11. PubMed ID: 26754633
    [Abstract] [Full Text] [Related]

  • 11. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E.
    Transfusion; 2012 Aug 01; 52(8):1785-91. PubMed ID: 22304442
    [Abstract] [Full Text] [Related]

  • 12. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
    Andreola G, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D.
    Eur J Haematol; 2012 Feb 01; 88(2):154-8. PubMed ID: 21992403
    [Abstract] [Full Text] [Related]

  • 13. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
    Cashen AF, Rettig M, Gao F, Smith A, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J.
    Biol Blood Marrow Transplant; 2017 Aug 01; 23(8):1282-1289. PubMed ID: 28476490
    [Abstract] [Full Text] [Related]

  • 14. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
    Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, Urbaniak-Kujda D, Dybko J, Zielinska P, Dabrowska-Iwanicka A, Werkun J, Rzepecki P, Wroblewska W, Wiktor-Jedrzejczak W.
    Ann Hematol; 2011 May 01; 90(5):557-68. PubMed ID: 20938660
    [Abstract] [Full Text] [Related]

  • 15. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, Dodero A, Montefusco V, Carlo-Stella C, Corradini P.
    Leuk Lymphoma; 2014 Feb 01; 55(2):331-6. PubMed ID: 23656194
    [Abstract] [Full Text] [Related]

  • 16. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ.
    Transfusion; 2011 Sep 01; 51(9):1995-2000. PubMed ID: 21392017
    [Abstract] [Full Text] [Related]

  • 17. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.
    Pharmacotherapy; 2012 Jul 01; 32(7):596-603. PubMed ID: 22760691
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients].
    Guan FS, He DH, Li Y, Zhang Y, Zheng GF, Zhu YY, He JS, Zhang EF, Cai Z, Zhao Y.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug 01; 31(4):1056-1060. PubMed ID: 37551477
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
    Micallef IN, Stiff PJ, Stadtmauer EA, Bolwell BJ, Nademanee AP, Maziarz RT, Partisano AM, Marulkar S, DiPersio JF.
    Am J Hematol; 2013 Dec 01; 88(12):1017-23. PubMed ID: 23907769
    [Abstract] [Full Text] [Related]

  • 20. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G.
    Bone Marrow Transplant; 2010 Jan 01; 45(1):39-47. PubMed ID: 19483760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.